| |
|
|
|
|
|
Sierra Oncology Reports Third Quarter 2020 Results
|
|
Vancouver, BC, November 18, 2020--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, reported its financial and operational results for the third quarter ended September 30, 2020.
|
|
|
|
|
|
|
|
|
|
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib
|
|
Vancouver, BC, June 1, 2020--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that Dose Intensity and Long-Term Safety data for momelotinib will be presented at the 25th European Hematology Association (EHA) Virtual Congress.
|
|
|
|
|
|
|
|
Sierra Oncology Reports 2019 Year End Results
|
|
Vancouver, BC, March 5, 2020--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, reported its financial and operational results for the year ended December 31, 2019.
|
|
|
|
|
|
|
|
|
|
Vancouver-based Sierra Oncology Announces 1-FOR-40 Reverse Stock Split
|
|
Vancouver, BC, January 22, 2020--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that its board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-40.
|
|
|
|
|
|
|
|
Vancouver-based Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial
|
|
Vancouver, BC, November 22, 2019--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that it has launched the MOMENTUM clinical trial for patients with myelofibrosis.
|
|
|
|
|
|
|
|
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
|
|
Vancouver, BC, November 15, 2019--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that it has agreed to amend its Asset Purchase Agreement with Gilead Sciences, Inc. for momelotinib (upon Sierra closing a qualified financing).
|
|
|
|
|
|
|
|
Sierra Oncology Reports Third Quarter 2019 Results
|
|
Vancouver, BC, November 7, 2019--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, reported its financial and operational results for the third quarter ended September 30, 2019.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
